Research programme: dual amylin and calcitonin receptor agonists - Viking Therapeutics
Latest Information Update: 26 Jul 2024
At a glance
- Originator Viking Therapeutics
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Amylin receptor agonists; Calcitonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes mellitus; Obesity